Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 4/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604217 | 1.00 | LMNA (0.49) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL4605267 | 0.96 | LMNA (0.49) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL27114706 | 0.88 | MAPT (0.48) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL27114697 | 0.88 | MAPT (0.48) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL7705443 | 0.88 | LMNA (0.66) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL30932037 | 0.86 | LMNA (0.69) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL31045425 | 0.86 | LMNA (0.69) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL7050991 | 0.86 | LMNA (0.69) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL2309506 | 0.86 | LMNA (0.69) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL29169810 | 0.86 | LMNA (0.69) | LMNAKDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122787-A1 | METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE (PKD) OR OTHER CYST FORMING DISEASES | STOWERS INSTITUTE FOR MEDICAL RESEARCH | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122787-A1 | METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE (PKD) OR OTHER CYST FORMING DISEASES | PKD2, PKD1, HDAC4 | LMNA 1021/4885KDM4E 852/4885DUSP3 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.